RB1 and lung carcinoma: Figure 1 shows frequencies of aberrations in the Cyclin D-CDK4/6-Rb pathway related genes in NSCLC from the publicly available cBioportal webpage: Pan-Lung Cancer (TCGA, Nat Genet 2016). Therefore, CDK4/6 has been a key target for the clinical development for cancer therapy (9, 10).